Abcellera Biologics Net Worth
Abcellera Biologics Net Worth Breakdown | ABCL |
Abcellera Biologics Net Worth Analysis
Abcellera Biologics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Abcellera Biologics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Abcellera Biologics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Abcellera Biologics' net worth analysis. One common approach is to calculate Abcellera Biologics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Abcellera Biologics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Abcellera Biologics' net worth. This approach calculates the present value of Abcellera Biologics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Abcellera Biologics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Abcellera Biologics' net worth. This involves comparing Abcellera Biologics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Abcellera Biologics' net worth relative to its peers.
Enterprise Value |
|
To determine if Abcellera Biologics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Abcellera Biologics' net worth research are outlined below:
| Abcellera Biologics is way too risky over 90 days horizon | |
| Abcellera Biologics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 28.83 M. Net Loss for the year was (162.86 M) with loss before overhead, payroll, taxes, and interest of (147.35 M). | |
| Abcellera Biologics currently holds about 868.21 M in cash with (108.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.04. | |
| Roughly 23.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635 IOVA ... |
Abcellera Biologics Quarterly Good Will |
|
Abcellera Biologics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Abcellera Biologics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Abcellera Biologics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Abcellera Biologics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Abcellera Biologics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Abcellera Biologics backward and forwards among themselves. Abcellera Biologics' institutional investor refers to the entity that pools money to purchase Abcellera Biologics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Prosight Management, Lp | 2025-03-31 | 2.8 M | Two Sigma Advisers, Llc | 2025-03-31 | 2.6 M | Tang Capital Management Llc | 2025-03-31 | 2.6 M | Citadel Advisors Llc | 2025-03-31 | 1.8 M | Guardian Partners Inc. | 2025-03-31 | 1.8 M | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 1.3 M | Norges Bank | 2024-12-31 | 1.3 M | Novo A/s | 2025-03-31 | 1.1 M | Federated Hermes Inc | 2025-03-31 | 947.8 K | Baker Bros Advisors Lp | 2025-03-31 | 27.5 M | Ing Investment Management Llc | 2025-03-31 | 21.2 M |
Follow Abcellera Biologics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.34 B.Market Cap |
|
Project Abcellera Biologics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.13) | (0.12) | |
| Return On Capital Employed | (0.25) | (0.23) | |
| Return On Assets | (0.12) | (0.11) | |
| Return On Equity | (0.15) | (0.15) |
When accessing Abcellera Biologics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Abcellera Biologics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Abcellera Biologics' profitability and make more informed investment decisions.
Evaluate Abcellera Biologics' management efficiency
Abcellera Biologics has return on total asset (ROA) of (0.1294) % which means that it has lost $0.1294 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.156) %, meaning that it created substantial loss on money invested by shareholders. Abcellera Biologics' management efficiency ratios could be used to measure how well Abcellera Biologics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to -0.12 this year. Return On Capital Employed is expected to rise to -0.23 this year. At this time, Abcellera Biologics' Net Tangible Assets are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 101.4 M this year, although the value of Non Current Assets Total will most likely fall to about 367.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.59 | 2.15 | |
| Tangible Book Value Per Share | 3.28 | 1.84 | |
| Enterprise Value Over EBITDA | (3.78) | (3.59) | |
| Price Book Value Ratio | 0.82 | 0.78 | |
| Enterprise Value Multiple | (3.78) | (3.59) | |
| Price Fair Value | 0.82 | 0.78 | |
| Enterprise Value | 771.4 M | 732.8 M |
Abcellera Biologics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue 34.6021 | Revenue | Quarterly Revenue Growth (0.57) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Abcellera Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Abcellera Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Abcellera Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Abcellera Biologics time-series forecasting models is one of many Abcellera Biologics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Abcellera Biologics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Abcellera Biologics Earnings per Share Projection vs Actual
Abcellera Biologics Corporate Management
| Andy Clark | Head Assurance | Profile | |
| Veronique Lecault | COO Director | Profile | |
| Bo Barnhart | Scientific Director | Profile | |
| Andrew MBA | Chief Officer | Profile | |
| EdD CEC | Senior Development | Profile | |
| Paul Colussi | Site Technologies | Profile | |
| JD Esq | Chief Officer | Profile |
Already Invested in Abcellera Biologics?
The danger of trading Abcellera Biologics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Abcellera Biologics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Abcellera Biologics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Abcellera Biologics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Abcellera Biologics is a strong investment it is important to analyze Abcellera Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Abcellera Biologics' future performance. For an informed investment choice regarding Abcellera Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.459 | Earnings Share (0.56) | Revenue Per Share | Quarterly Revenue Growth (0.57) | Return On Assets |
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.